// App-Quantinova.ai

EXTH-10 : COMBINATION OF EPIGENETIC ENZYME INHIBITORS, GSK-J4 AND BELINOSTAT, REVEALS HIGH EFFICACY IN IDH1 MUTANT GLIOMAS

Researchers

Presenter

  • Alisan Kayabolen

Principal Investigators

  • Gizem Nur Sahin

  • Fidan Seker

  • Ahmet Cingoz

  • Bekir Isik

  • Simge Acar

  • Hiroaki Wakimoto

  • Daniel Cahill

  • Ihsan Solaroglu

  • Adam Cribbs

  • Udo Oppermann

  • Tugba Bagci-Onder

Medical Centers

  • Marmara University School of Medicine, Istanbul, Turkey

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

  • NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

  • Botnar Research Centre, Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom

Locations

  • Turkey

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Low-grade gliomas

Biomarkers

  • DNA Damage Inducible Transcript 3

  • Isocitrate dehydrogenase 2

Drug/Treatment

  • 5-Azacytidine

  • belinostat Intravenous

  • GSKJ4

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved